BlueJet Healthcare Secures 102.48-Acre Land for Massive Expansion in Andhra Pradesh
Blue Jet Healthcare has acquired 102.48 acres of industrial land in Anakapalli District, Andhra Pradesh, for INR 41.87 crores. The company plans to invest up to INR 1,000 crores in Phase I to build a state-of-the-art manufacturing facility with a capacity of 1,000 KL. The project, expected to be operational by FY 2028-29, will be financed through internal accruals, equity, and debt. This expansion aims to support growth, enter new product verticals, and strengthen strategic relationships in the pharmaceutical industry.
31Jul 25
Blue Jet Healthcare Secures 102.48-Acre Land for INR 1,000 Crore Manufacturing Facility in Andhra Pradesh
Blue Jet Healthcare Limited has acquired 102.48 acres of industrial land in Anakapalli District, Andhra Pradesh, for INR 41.87 crore. The company plans to invest up to INR 1,000 crore in Phase I to build a facility with a manufacturing capacity of 1,000 KL, expected to be operational by FY 2028-29. This expansion aims to support growth, enter new product verticals, and strengthen industry relationships. The project will be financed through internal accruals, equity, and debt.
22Jul 25
Blue Jet Healthcare Reports 141% Surge in Q1 Profit, Revenue More Than Doubles
Blue Jet Healthcare Limited, a specialty pharmaceutical manufacturer, reported impressive Q1 results. Profit soared 141% to ₹911.70 crore, while revenue more than doubled to ₹3,547.58 crore. EBITDA grew 173.3% to ₹1,210.00 crore, with margin improving to 34.1%. Growth was primarily driven by higher sales in Pharma Intermediates & API. Despite strong performance, shares fell 10% due to sequential decline in EBITDA and margins.
14May 25
Blue Jet Healthcare's Q4 Profit Soars to ₹1.1 Billion, Marking Significant Growth
Blue Jet Healthcare, a key player in the pharmaceutical sector, announced a significant increase in its fourth-quarter net profit. The company reported a net profit of ₹1.10 billion, up from ₹396.00 million in the same quarter last year, representing a year-over-year growth of 177.78%. This substantial profit growth demonstrates the company's strong financial performance and could potentially impact its market position and investor confidence positively.
09Apr 25
Blue Jet Healthcare Expands into Chemical Intermediate Exports for Contrast Media Production
Blue Jet Healthcare has begun exporting a key chemical intermediate for gadolinium-based contrast media production in Q4FY25. This initiative is part of a collaboration with a European innovator partner. While not directly handling gadolinium, the company is now indirectly involved in the contrast media market, potentially opening new revenue streams. This move signifies Blue Jet's strategy to diversify its product portfolio and expand its global presence in the pharmaceutical ingredients market.